Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has submitted a routine compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2025. The certificate, issued by the company's Registrar and Share Transfer Agent (Beetal Financial & Computer Services Pvt Ltd), confirms that all securities received from Depository Participants for dematerialization during the quarter were properly accepted or rejected and listed on the stock exchanges. It also confirms that physical certificates were mutilated, cancelled, and the depository's name was substituted as the registered owner in the company's records within the required 15-day timeline. The filing is signed by Managing Director Yogesh Agrawal (DIN: 01165288) and RTA General Manager Punit Mittal.
This is a routine procedural compliance filing with no material impact on shareholders or the stock price. It simply confirms that share dematerialization requests were processed in line with SEBI rules during the January-March 2025 quarter.